Glycemic Management

Closed-loop insulin pump therapy is associated with more time in range compared with sensor-augmented therapy among older adults with type 1 diabetes, according to study findings published in Diabetes Care.

The first dose of a COVID-19 vaccine can cause a decline in interstitial glucose time in range for adults with type 1 diabetes, according to study findings published in Diabetic Medicine.

In an analysis of HbA1c data from 22 nations, most children and adults with type 1 diabetes do not have an HbA1c of less than 7.5%, though glycemic control varies greatly by age and country, according to study data.

Mean HbA1c for people with type 1 diabetes increased in the U.S. from 2011 to 2017, whereas Sweden saw decreases in HbA1c among all age groups, and Germany and Austria reported a decline among children, according to study data.

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Jane K. Dickinson, RN, PhD, CDCES, about the recent changes in terminology and abbreviations in the world of diabetes self-management education and support.

Fast-acting insulin aspart provides similar time in range as insulin aspart for adults with type 1 diabetes engaging in moderate- or high-intensity exercise, according to study findings published in Diabetes Technology & Therapeutics.

Susan was diagnosed with type 1 diabetes half a century ago, at age 2 years. Management in the decades since has certainly changed, yet she has thrived.

A cohort of U.S. children with type 1 diabetes had a decrease in mean glucose level and glucose management indicator during the first year of the COVID-19 pandemic compared with the prior year, according to study data.

Using the glucose management indicator, continuous glucose monitoring and time in range can improve glycemic control and health outcomes for people with diabetes, according to a speaker at the Cardiometabolic Health Congress.

Children with type 1 diabetes who used an advanced hybrid closed-loop insulin delivery system for 1 year achieved an average time in range of 74%, surpassing clinical consensus guidelines, according to European data released by Medtronic.